Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jul;8(3):280-3.
doi: 10.1215/15228517-2006-003. Epub 2006 May 25.

Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature

Vanita Noronha  1 , Nancy Berliner, Karen K Ballen, Jill Lacy, Jean Kracher, Joachim Baehring, John W Henson
Affiliations
Review

Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature

Vanita Noronha et al. Neuro Oncol. 2006 Jul.

Abstract

The emergence of temozolomide as an effective alkylating agent with little acute toxicity or cumulative myelosuppression has led to protracted courses of chemotherapy for many patients with gliomas. Secondary, or treatment-related, myelodysplasia (t-MDS) and acute myelogenous leukemia (t-AML) are life-threatening complications of alkylating chemotherapy and have been reported in patients with primary brain tumors. We describe a case of temozolomide-related t-MDS/AML and discuss the clinical features of this condition. Administration of an alkylating agent in patient populations with long median survivals must be undertaken with an understanding of the potential for this treatment complication.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Time line of events from initial diagnosis of breast cancer to the onset of acute leukemia. Months are shown for key dates.
See this image and copyright information in PMC

References

    1. Ballen KK. New trends in umbilical cord blood transplantation. Blood. 2005;105:3786–3792. - PubMed
    1. Ballen KK, Gilliland DG, Guinan EC, Hsieh CC, Parsons SK, Rimm IJ, Ferrara JL, Bierer BE, Weinstein HJ, Antin JH. Bone marrow transplantation for therapy-related myelodysplasia: Comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737–743. - PubMed
    1. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer. 1999;81:1022–1030. - PMC - PubMed
    1. Genot JY, Krulik M, Poisson M, van Efferterre R, Renoux M, Audebert AA, Canuel C, Smadja N, Debray J. Two cases of acute leukemia following treatment of malignant glioma. Cancer. 1983;52:222–226. - PubMed
    1. Grewal J, Nestor V, Fink K. Long term use of monthly temozolomide in patients with oligodendroglioma: Feasibility and tolerability of two years of therapy. Neurology. 2005;64:A25. (abstract)

MeSH terms